A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors

NCT01725555 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Hematological Malignancies

Interventions

DRUG: Fasted treatment: AXL1717
DRUG: Fed treatment: AXL1717

Sponsor

Axelar AB